Biocartis Group NV: Biocartis to host webcast for announcement 2017 financial results on 1 March 2018



22 February 2018, 07:00 CET

BioCARTIS to Host Webcast FOR ANNOUNCEMENT 2017 FINANCIAL Results on 1 March 2018

Mechelen, Belgium, 22 February 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company, today announces that it will host a live webcast on Thursday, 1 March 2018 at 14:00 CET / 13:00 BST (UK) / 08:00 EDT (US) to announce its 2017 results and 2018 outlook.

The live webcast can be accessed on the Biocartis website or by clicking here. To participate in the questions and answers session, please dial in 5-10 minutes prior to the start time by using the numbers below, followed by the confirmation code 8419378. The webcast and conference call will be conducted in English. A replay of the webcast will be available on the Biocartis website ('investors') shortly after.

Conference call dial-ins:

  • London, United Kingdom (standard international):                          +44 (0)330 336 91 05
  • Brussels, Belgium:                                                                       +32 (0)2 404 06 59
  • Amsterdam, Netherlands:                                                             +31 (0) 20 721 92  51
  • Los Angeles, USA:                                                                       +1 323-994-2083
  • Paris, France:                                                                             +33 (0)1 76 77 22 74

Confirmation code:  8419378

----- END ----

More information:

Renate Degrave

Manager Corporate Communications & Investor Relations


tel         +32 15 631 729
mobile   +32 471 53 60 64

About Biocartis 

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers fourteen oncology tests and two infectious disease tests in Europe. More information: Press Photo Library available here. Follow us on Twitter: @Biocartis_.

Biocartis and Idylla(TM) are registered trademarks in Europe, the United States and other countries. Biocartis trademark and logo and Idylla(TM) trademark and logo are used trademarks belonging to Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements

This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements.